Drug Trial Radar · NCT06147648
Early Conversion of Prolonged-release Tacrolimus in Liver Transplantation.
Last checked: Nov 20, 2026Latest source record: Nov 27, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
352
Planned (sponsor's estimate)
Start
Dec 1, 2023
Primary completion
Jul 30, 2025
Study completion Jul 30, 2026
Sponsor
- Lead sponsor
- Beijing Tsinghua Chang Gung HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Nov 27, 2023
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Tacrolimus is a commonly used immunosuppressant after liver transplantation. A once-daily administration of prolonged-release tacrolimus has been found to improve patient compliance and offer good efficacy and safety. Moreover, there is evidence that this prolonged-release formulation mitigates renal impairment and metabolic syndrome in transplant recipients. Foreign studies have confirmed that it is safe and feasible for liver transplant recipients to switch from immediate-release tacrolimus to prolonged-release tacrolimus during the stable period. At the same time, patients with early conversion are more likely to benefit in terms of graft survival and renal function recovery, and the proportion of drug conversion needs to be further explored. This study aims to assess the efficacy and safety of switching from immediate-release tacrolimus to prolonged-release tacrolimus three months after liver transplantation. Furthermore, it seeks to investigate the impact of this conversion on indicators such as liver function, kidney function, metabolic disease incidence, and infection incidence in patients.
Conditions
- Liver Transplantation
Interventions
Tacrolimus Sustained-release CapsulesDrug
Transition from Immediate-release tacrolimus to prolonged-release tacrolimus at 3 months after liver transplantation
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of biopsy-confirmed acute rejection (BPAR) within 3, 6, and 12 months after conversionTime frame: within 3, 6, and 12 months after conversion
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.